Analysis of FDA FY2018 Drug GMP Warning Letters

By Barbara W. Unger

Identify new FDA inspection trends to proactively address similar situations in your company.


Topics of this report include:

  • Type of manufacture (API, dosage form, API and dosage form, compounding pharmacy/outsourcing facility), and country associated with the warning letter.
  • Particular targets of warning letters issued this year, including OTC drug products, drug product manufacturers, data integrity and contracted operations.
  • Interval between the inspection and enforcement actions, including issuance of a warning letter or import alert.

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.